TWi Pharmaceuticals USA Announces the Receipt of State Sales Licenses from All 50 States in the U.S.

April 17, 2015.  TWi Pharmaceuticals, Inc. (“TWi”, Stock Ticker:4180.TT) today announced that its fully-owned subsidiary, TWi Pharmaceuticals USA, has obtained state sales licenses from all 50 states in the United States.  It has been in close contact with the major nationwide retail pharmacy distributors and wholesalers and expects to have its own label specialty generic products sold through these nationwide pharmacy distribution channels soon in the U.S. pharma market.

According to IMS Health, the U.S. pharma market is the world's largest pharmaceutical consumption market.  Its generic pharma market value exceeds US$60 billion.

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States. For more information of TWi Pharmaceuticals, please visit www.twipharma.com.

Eric Lin
Investor Relations
Tel: +886-2-2657-3350 ext. 407
Email: eric.lin@twipharma.com